

Reviewer 1

Q: It is obvious that this is a very interesting study, especially since there has been no report on the use of Bev+CTX+OXA to treat PMP. The authors suggested that Bev+CTX+OXA regimen is certain effective in the posterior line treatment of advanced pseudomyxoma peritonei, and the adverse reactions can be tolerated. The preoperative increase of Ca125 is an independent prognostic factor of PFS. The limitations are sufficiently described by the authors. However, the discussion should be expanded. I would recommend giving references to past studies on feasible treatment options of PMP patients. In addition, abstracts need to be modified to have structured. In conclusion, the manuscript will be recommended to be published after a minor revision.

A: Thanks for the reviewer positive comments on our study, according to the comments, we have expanded the discussion section, and the abstract section have been structured. In addition, we have also carefully checked the whole manuscript.

Reviewer 2

Q: Although there were only 32 patients in this retrospective study, the authors conducted a rich data analysis. The authors analyzed PFS, ORR, DCR, median follow-up time, evaluated serum tumor markers, and adverse events during the study period. The manuscript is well written: the title reflects the main subject of the article, abstract and keywords well summarize the arguments. The methodology is described in detail and is well structured. The discussion is well articulated according to results and the authors have clearly underlined the limitations and drawbacks of the manuscript. However, discussion also could be improved (which would enhance readability and flow).

A: Thanks. We have revised the discussion section.